Abstract
The key genes involved in the development of esophageal squamous cell carcinoma (ESCC) remain to be elucidated. Previous studies indicate extensive genomic alterations occur on chromosome 9 in ESCC. Using a monochromosome transfer approach, this study provides functional evidence and narrows down the critical region (CR) responsible for chromosome 9 tumor suppressing activity to a 2.4 Mb region mapping to 9q33–q34 between markers D9S1798 and D9S61. Interestingly, a high prevalence of allelic loss in this CR is also observed in primary ESCC tumors by microsatellite typing. Allelic loss is found in 30/34 (88%) tumors and the loss of heterozygosity (LOH) frequency ranges from 67 to 86%. Absent to low expression of a 9q32 candidate tumor suppressor gene (TSG), DEC1 (deleted in esophageal cancer 1), is detected in four Asian ESCC cell lines. Stably expressing DEC1 transfectants provide functional evidence for inhibition of tumor growth in nude mice and DEC1 expression is decreased in tumor segregants arising after long-term selection in vivo. There is 74% LOH in the DEC1 region of ESCC primary tumors. This study provides the first functional evidence for the presence of critical tumor suppressive regions on 9q33–q34. DEC1 is a candidate TSG that may be involved in ESCC development.
Similar content being viewed by others
References
Aoki T, Mori T, Du X, Nishihira T, Matsubara T and Nakamura Y . (1994). Genes Chromosome Cancer, 10, 177–182.
Cheng Y, Poulos NE, Lung ML, Hampton G, Ou B, Lerman MI and Stanbridge EJ . (1998). Proc. Natl. Acad. Sci. USA, 95, 3042–3047.
Cheng Y, Stanbridge EJ, Kong H, Bengtsson U, Lerman MI and Lung ML . (2000). Genes Chromosome Cancer, 28, 82–91.
Chow LS, Lo KW, Kwong J, To KF, Tsang KS, Lam CW, Dammann R and Huang DP . (2004). Int. J. Cancer, 109, 839–847.
Fogh J, Fogh JM and Orfeo T . (1977). J. Natl. Cancer Inst., 59, 221–226.
Gorgoulis VG, Koutroumbi EN, Kotsinas A, Zacharatos P, Markopoulos C, Giannikos L, Kyriakou V, Voulgaris Z, Gogas I and Kittas C . (1998). Mol. Med., 4, 807–822.
Goyette MC, Cho K, Fasching CL, Levy DB, Kinzler KW, Paraskeva C, Vogelstein B and Stanbridge EJ . (1992). Mol. Cell. Biol., 12, 1387–1395.
Grady B, Goharderakhshan R, Chang J, Ribeiro-Filho LA, Perinchery G, Franks J, Presti J, Carroll P and Dahiya R . (2001). J. Urol., 166, 1088–1092.
Habuchi T, Luscombe M, Elder PA and Knowles MA . (1998). Genomics, 48, 277–288.
He C, Zhang X, Wang Y, Sun K and Chen HD . (1999). Chin. Med. J., 112, 497–500.
Holmberg E, Rozell BL and Toftgard R . (1996). Br. J. Cancer, 74, 246–250.
Hu CP, Hsieh HG, Chien KY, Wang PY, Wang CI, Chen CY, Lo SJ, Wu KD and Chang CM . (1984). J. Natl. Cancer Inst., 72, 577–583.
Hu YC, Lam KY, Law SY, Wan TS, Ma ES, Kwong YL, Chan LC, Wong J and Srivastava G . (2002). Cancer Genet. Cytogenet., 135, 120–127.
Huang Y, Boynton RF, Blount PL, Silverstein RJ, Yin J, Tong Y, McDaniel TK, Newkirk C, Resau JH, Sridhara R, Reid BJ and Meltzer SJ . (1992). Cancer Res., 52, 6525–6530.
Jagasia AA, Block JA, Qureshi A, Diaz MO, Nobori T, Gitelis S and Iyer AP . (1996). Cancer Lett., 105, 91–103.
Karkera JD, Ayache S, Ransome Jr RJ, Jackson MA, Elsayem AF, Sridhar R, Detera-Wadleigh SD and Wadleigh RG . (2000). Clin. Cancer Res., 6, 3565–3569.
Kwong FM, Tang JC, Srivastava G and Lung ML . (2004). Cancer Lett., 208, 207–213.
Li M, Makkinje A and Damuni Z . (1996). J. Biol. Chem., 271, 11059–11162.
Marshall B, Isidro G, Martins AG and Boavida MG . (1997). Cancer Genet. Cytogenet., 96, 134–139.
Miura K, Suzuki K, Tokino T, Isomura M, Inazawa J, Matsuno S and Nakamura Y . (1996). Cancer Res., 56, 1629–1634.
Mori T, Yanagisawa A, Kato Y, Miura K, Nishihira T, Mori S and Nakamura Y . (1994). Hum. Mol. Genet., 3, 1969–1971.
Murakami Y . (2002). Oncogene, 21, 6936–6948.
Muzeau F, Flejou JF, Thomas G and Hamelin R . (1997). Int. J. Cancer, 72, 27–30.
Naidoo R, Tarin M, Reddi A and Chetty RD . (1999). Diagn. Mol. Pathol., 8, 131–137.
Nishiwaki T, Daigo Y, Kawasoe T and Nakamura Y . (2000). Genes Chromosome Cancer, 27, 169–176.
Nishiyama H, Takahashi T, Kakehi Y, Habuchi T and Knowles MA . (1999). Genes Chromosome Cancer, 26, 171–175.
Pack SD, Karkera JD, Zhuang Z, Pak ED, Balan KV, Hwu P, Park WS, Pham T, Ault DO, Glaser M, Liotta L, Detera-Wadleigh SD and Wadleigh RG . (1999). Genes Chromosome Cancer, 25, 160–168.
Parker WL, Goldring MB and Philip A . (2003). J. Bone Miner. Res., 18, 289–302.
Parris CN, Harris JD, Griffin DK, Cuthbert AP, Silver AJR and Newbold RF . (1999). Cancer Res., 59, 516–520.
Qin P, Haberbusch JM, Soprano KJ and Soprano DR . (2004). J. Cell. Biochem., 92, 147–163.
Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST, Tsao SW and Tao Q . (2004). Oncogene, 23, 4793–4806.
Sampson JR, Patel A and Mee AD . (1995). J. Med. Genet., 32, 848–850.
Saxon PJ, Srivatsan ES, Leipzig GV, Sameshima JH and Stanbridge EJ . (1985). Mol. Cell. Biol., 5, 140–146.
Shibagaki, Shimada Y, Wagata T, Ikenaga M, Imamura M and Ishizaki K . (1994). Cancer Res., 54, 2996–3000.
Stanbridge EJ and Wilkinson J . (1978). Natl. Acad. Sci. USA, 75, 1466–1469.
Tada K, Oka M, Hayashi H, Tangoku A, Oga A and Sasaki K . (2000). Cancer Genet. Cytogenet., 117, 108–112.
Takahashi K, Kanazama H, Chan CT, Hosono T, Takahara M and Sato K . (1990). Jpn. J. Oral Maxillofac. Surg., 36, 307–316.
Tang JCO, Wan TSK, Wong N, Pang E, Lam KY, Law SY, Chow LMC, Ma ESK, Chan LC, Wong J and Srivastava G . (2001). Cancer Genet. Cytogenet., 124, 36–41.
Wang L, Li W, Wang X, Zhang C, Zhang T, Mao X and Wu M . (1996). Oncogene, 12, 699–703.
Wiest JS, Franklin WA, Otstot JT, Forbey K, Varella-Garcia M, Rao K, Drabkin H, Gemmill R, Ahrent S, Sidransky D, Saccomanno G, Fountain JW and Anderson MW . (1997). Cancer Res., 57, 1–6.
Wu Q, Possati L, Montesi M, Gualandi F, Rimessi P, Morelli C, Trabanelli C and Barbanti-Brodano G . (1996). Int. J. Cancer, 65, 840–846.
Yamada H, Wake N, Fujimoto S, Barrett JC and Oshimura M . (1990). Oncogene, 5, 1141–1147.
Yang LC, Tang CMC, Lau KW and Lung ML . (2004). Cancer Lett., 203, 71–77.
Yen CC, Chen YJ, Chen JT, Hsia JY, Chen PM, Liu JH, Fan FS, Chiou TJ, Wang WS and Lin CH . (2001). Cancer, 92, 2769–2777.
Yen CC, Chen YJ, Lu KH, Hsia JY, Chen JT, Hu CP, Chen PM, Liu JH, Chiou TJ, Wang WS, Yang MH, Chao TC and Lin CH . (2003). Int. J. Oncol., 23, 871–881.
Acknowledgements
We thank Y Cheng and HL Lung for helpful discussions during manuscript preparation. We would like to acknowledge the financial support of the Research Grants Council of the Hong Kong Special Administration Region, China (HKUST) to MLL, for HKUST 6106/00M grant.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, L., Leung, A., Ko, J. et al. Tumor suppressive role of a 2.4 Mb 9q33–q34 critical region and DEC1 in esophageal squamous cell carcinoma. Oncogene 24, 697–705 (2005). https://doi.org/10.1038/sj.onc.1208179
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208179
- Springer Nature Limited
Keywords
This article is cited by
-
Mir-208 promotes cell proliferation by repressing SOX6 expression in human esophageal squamous cell carcinoma
Journal of Translational Medicine (2014)
-
The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damage
Oncogenesis (2012)
-
MicroRNA-203 inhibits cell proliferation by repressing ΔNp63 expression in human esophageal squamous cell carcinoma
BMC Cancer (2011)
-
Abrogated expression of DEC1 during oesophageal squamous cell carcinoma progression is age- and family history-related and significantly associated with lymph node metastasis
British Journal of Cancer (2011)
-
Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC
Oncogene (2008)